TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.

Authors:
Filipiak KJ; Babkowski MC; Cameli M; Carugo S; Ferri C and 7 more

Journal:
Cardiol J

Publication Year: 2022

DOI:
10.5603/CJ.a2022.0087

PMCID:
PMC9550320

PMID:
36117294

Journal Information

Full Title: Cardiol J

Abbreviation: Cardiol J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: Krzysztof J. Filipiak — Adamed, Alfasigma, AstraZeneca, Bausch Health, Bayer, Boehringer Ingelheim, Krka, Mundipharma, Mylan, Novartis, Sandoz, Servier, Viatris; Miguel Camafort Babkowski — Adamed; Matteo Cameli — Adamed, AstraZeneca, Novo Nordisk, General Electric; Stefano Carugo — Adamed; Claudio Ferri — Adamed; Djamshid B. Irisov — Adamed; Krzysztof Narkiewicz — Adamed, Bausch Health, Berlin-Chemie/Menarini, Egis, Gedeon Richter, Idorsia, Krka, Medtronic, Novo Nordisk, Polpharma, Recordati, Servier; Ulugbek Nizamov — Adamed; Leopoldo Pérez de Isla — Adamed, Almirall, Amgen, Bayer, Esteve, Ferrer, MSD, Mylan, Novartis, Novo Nordisk, Organon, Pfizer, Sanofi, Servier; Anna Tomaszuk-Kazberuk — Adamed, Boehringer Ingelheim, Krka, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda; Andrea Ungar — Adamed; Aleksandra Gąsecka — Adamed, AstraZeneca, Bausch Health, Berlin-Chemie/Menarini, Krka, Servier."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025